Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3060) 3060
Book Chapter (29) 29
Dissertation (18) 18
Magazine Article (7) 7
Publication (7) 7
Conference Proceeding (2) 2
Newsletter (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ezetimibe (2653) 2653
science & technology (2039) 2039
humans (1982) 1982
life sciences & biomedicine (1953) 1953
male (1080) 1080
anticholesteremic agents - therapeutic use (1020) 1020
female (933) 933
azetidines - therapeutic use (882) 882
middle aged (793) 793
statins (740) 740
drug therapy, combination (720) 720
cholesterol (715) 715
cardiovascular system & cardiology (709) 709
cholesterol, ldl - blood (683) 683
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (598) 598
aged (593) 593
hypercholesterolemia - drug therapy (588) 588
cardiac & cardiovascular systems (564) 564
pharmacology & pharmacy (551) 551
treatment outcome (509) 509
lipids (464) 464
anticholesteremic agents - administration & dosage (442) 442
biological and medical sciences (419) 419
azetidines - administration & dosage (408) 408
animals (404) 404
medical sciences (398) 398
adult (395) 395
azetidines - pharmacology (371) 371
hypercholesterolemia (370) 370
simvastatin - therapeutic use (363) 363
risk factors (360) 360
simvastatin (353) 353
anticholesteremic agents - pharmacology (338) 338
abridged index medicus (312) 312
atherosclerosis (312) 312
ezetimibe - therapeutic use (307) 307
low density lipoproteins (304) 304
anticholesteremic agents - adverse effects (290) 290
cardiovascular disease (290) 290
cardiovascular (278) 278
general & internal medicine (270) 270
medicine, general & internal (270) 270
peripheral vascular disease (264) 264
hypercholesterolemia - blood (254) 254
azetidines - adverse effects (253) 253
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (237) 237
double-blind method (235) 235
statin (235) 235
antilipemic agents (226) 226
cholesterol - metabolism (223) 223
cardiovascular diseases - prevention & control (222) 222
simvastatin - administration & dosage (221) 221
drug therapy (219) 219
cholesterol - blood (213) 213
dyslipidemias - drug therapy (211) 211
biochemistry & molecular biology (210) 210
drug combinations (203) 203
analysis (201) 201
pharmacology. drug treatments (197) 197
hypolipidemic agents - therapeutic use (196) 196
care and treatment (188) 188
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (180) 180
research (177) 177
coronary heart disease (174) 174
cardiology (172) 172
triglycerides - blood (168) 168
cardiovascular diseases (166) 166
cholesterol, hdl - blood (153) 153
atorvastatin calcium (152) 152
endocrinology & metabolism (150) 150
cholesterol, ldl - drug effects (147) 147
atorvastatin (146) 146
cardiology. vascular system (146) 146
time factors (145) 145
hyperlipidemias - drug therapy (144) 144
mice (144) 144
randomized controlled trials as topic (143) 143
biomarkers - blood (142) 142
chemistry (142) 142
aged, 80 and over (141) 141
lipoproteins (141) 141
physical sciences (141) 141
dose-response relationship, drug (139) 139
lipids - blood (139) 139
intestinal absorption - drug effects (138) 138
low density lipoprotein (138) 138
medicine & public health (138) 138
diabetes (135) 135
clinical trials (134) 134
ezetimibe - administration & dosage (133) 133
anticholesteremic agents (132) 132
triglycerides (132) 132
dyslipidemia (128) 128
clinical trials as topic (127) 127
hyperlipoproteinemia type ii - drug therapy (121) 121
cardiovascular agents (120) 120
prospective studies (118) 118
simvastatin - adverse effects (116) 116
ezetimibe, simvastatin drug combination (114) 114
medicine, research & experimental (113) 113
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2834) 2834
German (73) 73
Spanish (67) 67
Japanese (44) 44
French (42) 42
Czech (32) 32
Portuguese (28) 28
Russian (25) 25
Hungarian (24) 24
Chinese (14) 14
Italian (11) 11
Korean (8) 8
Polish (8) 8
Danish (6) 6
Turkish (5) 5
Swedish (3) 3
Dutch (2) 2
Finnish (2) 2
Norwegian (2) 2
Hebrew (1) 1
Lithuanian (1) 1
Persian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Development of a joint population pharmacokinetic model of ezetimibe and its conjugated metabolite
by Soulele, K and Karalis, V
European journal of pharmaceutical sciences, ISSN 0928-0987, 02/2019, Volume 128, pp. 18 - 26
Ezetimibe glucuronide | Joint population pharmacokinetic model | Enterohepatic recirculation | Ezetimibe | Glucuronides - pharmacokinetics | Hypolipidemic Agents - metabolism | Humans | Ezetimibe - metabolism | Azetidines - metabolism | Azetidines - pharmacokinetics | Azetidines - chemistry | Ezetimibe - blood | Ezetimibe - chemistry | Glucuronides - metabolism | Models, Biological | Ezetimibe - pharmacokinetics | Drug Compounding | Adult | Hypolipidemic Agents - chemistry | Hypolipidemic Agents - pharmacokinetics | Glucuronides - chemistry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effect of hydroxypropylcellulose and Tween 80 on physicochemical properties and bioavailability of ezetimibe-loaded solid dispersion
by Rashid, Rehmana and Kim, Dong Wuk and Din, Fakhar ud and Mustapha, Omer and Yousaf, Abid Mehmood and Park, Jong Hyuck and Kim, Jong Oh and Yong, Chul Soon and Choi, Han-Gon
Carbohydrate polymers, ISSN 0144-8617, 10/2015, Volume 130, pp. 26 - 31
Solid dispersion | Bioavailability | Tween 80 | Ezetimibe | Solubility | Hydroxypropylcellulose | Physical Sciences | Chemistry | Chemistry, Organic | Polymer Science | Chemistry, Applied | Science & Technology | Polysorbates - chemistry | Administration, Oral | Biological Availability | Male | Ezetimibe - administration & dosage | Rats, Sprague-Dawley | Drug Carriers - chemistry | Cellulose - chemistry | Animals | Ezetimibe - chemistry | Ezetimibe - pharmacokinetics | Surface-Active Agents - chemistry | Cellulose - analogs & derivatives | Surface active agents | Pharmacy | Antilipemic agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: The ODYSSEY COMBO II randomized controlled trial
by Cannon, Christopher P and Cariou, Bertrand and Blom, Dirk and McKenney, James M and Lorenzato, Christelle and Pordy, Robert and Chaudhari, Umesh and Colhoun, Helen M and ODYSSEY COMBO II Investigators
European heart journal, ISSN 0195-668X, 05/2015, Volume 36, Issue 19, pp. 1186 - 1194
Alirocumab | Monoclonal antibody | Low-Density Lipoprotein Cholesterol | Ezetimibe | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Double-Blind Method | Drug Administration Schedule | Ezetimibe - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Treatment Outcome | Ezetimibe - administration & dosage | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Injections, Subcutaneous | Cholesterol, LDL - metabolism | Female | Index Medicus | Track Clinical Paper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
by Cannon, Christopher P and Blazing, Michael A and Giugliano, Robert P and McCagg, Amy and White, Jennifer A and Theroux, Pierre and Darius, Harald and Lewis, Basil S and Ophuis, Ton Oude and Jukema, J. Wouter and De Ferrari, Gaetano M and Ruzyllo, Witold and De Lucca, Paul and Im, KyungAh and Bohula, Erin A and Reist, Craig and Wiviott, Stephen D and Tershakovec, Andrew M and Musliner, Thomas A and Braunwald, Eugene and Califf, Robert M and IMPROVW-IT Investigators and IMPROVE-IT Investigators
The New England journal of medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cardiology and cardiovascular system | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial
by Nissen, Steven E and Stroes, Erik and Dent-Acosta, Ricardo E and Rosenson, Robert S and Lehman, Sam J and Sattar, Naveed and Preiss, David and Bruckert, Eric and Češka, Richard and Lepor, Norman and Ballantyne, Christie M and Gouni-Berthold, Ioanna and Elliott, Mary and Brennan, Danielle M and Wasserman, Scott M and Somaratne, Ransi and Scott, Rob and Stein, Evan A and Sullivan, David and Kostner, Karam and Don Wauchope, Andrew and Hartleib, Michael and Baass, Alexis and Bergeron, Jean and Joy, Tisha and Adamkova, Vera and Blaha, Vladimir and Jeppesen, Jorgen and Jensen, Henrik Kjaerulf and Krempf, Michel and Bully, Chantal and Bosiljanoff, Peter and Steinhagen-Thiessen, Elisabeth and Pintus, Paolo and Borghi, Claudio and Sampietro, Tiziana and Vigna, Giovanni Battista and Mannarino, Elmo and Pozzi, Claudio and Liem, Anho and Van Leendert, Rudolf and Scott, Russell and Kjaernli, Thorbjorn and Langslet, Gisle and Jacovides, Andrew and Klug, Eric and Blom, Dirk and Neely, Dermot and Dawson, Charlotte and Miller, Michael and McCullum, Kevin and Rocco, Michael and Shah, Prediman and Rosenblit, Paul and Pokrywka, Gregory and Blazing, Michael and Toth, Peter and Moriarty, Patrick and Rubenfire, Melvyn and Morris, Pamela and Quyyumi, Arshed and Kopecky, Stephen and GAUSS-3 Investigators
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1580 - 1590
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myalgia - blood | Myalgia - chemically induced | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Myositis - chemically induced | Hypercholesterolemia - drug therapy | Myositis - prevention & control | Time Factors | Adult | Cholesterol, LDL - blood | Female | Muscular Diseases - prevention & control | Ezetimibe - therapeutic use | Muscular Diseases - chemically induced | Atorvastatin Calcium - adverse effects | Hypercholesterolemia - blood | Myalgia - prevention & control | Creatine Kinase - blood | Double-Blind Method | Ezetimibe - adverse effects | Biomarkers - blood | Myositis - blood | Anticholesteremic Agents - adverse effects | Muscular Diseases - blood | Rhabdomyolysis - prevention & control | Cross-Over Studies | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Rhabdomyolysis - chemically induced | Rhabdomyolysis - blood | Side effects | Muscular system | Comparative analysis | Drug therapy | Low density lipoprotein | Statins
Journal Article
Details down arrow
6. Full Text Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel
by Ference, Brian A and Ginsberg, Henry N and Graham, Ian and Ray, Kausik K and Packard, Chris J and Bruckert, Eric and Hegele, Robert A and Krauss, Ronald M and Raal, Frederick J and Schunkert, Heribert and Watt, Gerald F and Borén, Jan and Fazio, Sergio and Horton, Jay D and Masana, Luis and Nicholls, Stephen J and Nordestgaard, Børge G and Van De Sluis, Bart and Taskinen, Marja-Riitta and Tokgözoǧlu, Lale and Landmesser, Ulf and Laufs, Ulrich and Wiklund, Olov and Stock, Jane K and Chapman, M. John and Catapano, Alberico L
European heart journal, ISSN 0195-668X, 08/2017, Volume 38, Issue 32, pp. 2459 - 2472
Low-density lipoprotein | Recommendations | Atherosclerosis | Ezetimibe | Clinical trials | Cardiovascular disease | PCSK9 | Mendelian randomization | Statin | Causality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases
by Pirillo, A and Catapano, A.L and Norata, G.D
Current medicinal chemistry, ISSN 0929-8673, 03/2016, Volume 23, Issue 10, pp. 983 - 999
Cardiovascular disease | Cholesterol absorption | LDL-C | NPC1L1 | Cholesterol | Ezetimibe | Pharmacology & Pharmacy | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Ezetimibe - chemistry | Cardiovascular Diseases - metabolism | Membrane Proteins - antagonists & inhibitors | Simvastatin - chemistry | Cardiovascular Diseases - drug therapy | Humans | Ezetimibe - pharmacology | Simvastatin - pharmacology | Ezetimibe - chemical synthesis
Journal Article
Details down arrow
8. Full Text Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
by Farnier, Michel and Jones, Peter and Severance, Randall and Averna, Maurizio and Steinhagen-Thiessen, Elisabeth and Colhoun, Helen M and Du, Yunling and Hanotin, Corinne and Donahue, Stephen
Atherosclerosis, ISSN 0021-9150, 2015, Volume 244, pp. 138 - 146
Cardiovascular | PCSK9 | Rosuvastatin | Alirocumab | Monoclonal antibody | Low-density lipoprotein cholesterol | Ezetimibe | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hypercholesterolemia - blood | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Cholesterol, LDL - drug effects | Treatment Outcome | Ezetimibe - administration & dosage | Hypercholesterolemia - drug therapy | Rosuvastatin Calcium - administration & dosage | Dose-Response Relationship, Drug | Time Factors | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Injections, Subcutaneous | Cardiovascular Diseases - blood | Cholesterol, LDL - blood | Retrospective Studies | Drug Therapy, Combination | Cardiac patients | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Evaluation of physicochemical properties and in vivo efficiency of atorvastatin calcium/ezetimibe solid dispersions
by Jahangiri, Azin and Barzegar-Jalali, Mohammad and Garjani, Alireza and Javadzadeh, Yousef and Hamishehkar, Hamed and Asadpour-Zeynali, Karim and Adibkia, Khosro
European journal of pharmaceutical sciences, ISSN 0928-0987, 01/2016, Volume 82, pp. 21 - 30
Atorvastatin | Solid dispersion | In vivo evaluation | Ezetimibe | Liver steatosis | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Liver - pathology | Hyperlipidemias - blood | Rats, Wistar | Atorvastatin Calcium - pharmacology | Fatty Liver - blood | Fatty Liver - pathology | Atorvastatin Calcium - administration & dosage | Cholesterol - blood | Hyperlipidemias - drug therapy | Atorvastatin Calcium - chemistry | Ezetimibe - pharmacology | Solubility | Male | Ezetimibe - administration & dosage | Fatty Liver - drug therapy | Povidone - chemistry | Animals | Ezetimibe - chemistry | Liver - drug effects | Diet, High-Fat | Hyperlipidemias - pathology | Ezetimibe - therapeutic use | Atorvastatin Calcium - therapeutic use | Drug Combinations | Low density lipoproteins | Analysis | Liver | Antilipemic agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
by Ference, Brian A and Ginsberg, Henry N and Graham, Ian and Ray, Kausik K and Packard, Chris J and Bruckert, Eric and Hegele, Robert A and Krauss, Ronald M and Raal, Frederick J and Schunkert, Heribert and Watts, Gerald F and Boren, Jan and Fazio, Sergio and Horton, Jay D and Masana, Luis and Nicholls, Stephen J and Nordestgaard, Borge G and van de Sluis, Bart and Taskinen, Marja-Riitta and Tokgozoglu, Lale and Landmesser, Ulf and Laufs, Ulrich and Wiklund, Olov and Stock, Jane K and Chapman, M. John and Catapano, Alberico L and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
European heart journal, ISSN 0195-668X, 08/2017, Volume 38, Issue 32, pp. 2459 - 2472
METAANALYSIS | Ezetimibe | Clinical trials | Cardiovascular disease | PCSK9 | RISK | Mendelian randomization | Statin | Low-density lipoprotein | Recommendations | LDL CHOLESTEROL | TRIAL | GENERAL-POPULATION | STATIN THERAPY | HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | CHOLESTEROL-FED RABBITS | Atherosclerosis | Causality | CORONARY-HEART-DISEASE | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Genetic Predisposition to Disease - genetics | Cholesterol, HDL - metabolism | Lipoproteins, LDL - physiology | Hyperlipidemias - prevention & control | Consensus | Atherosclerosis - etiology | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Epidemiologic Methods | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cholesterol, LDL - metabolism | Ezetimibe - therapeutic use | Atherosclerosis - prevention & control | Index Medicus | Current Opinion | Kardiologi | Cardiac and Cardiovascular Systems
Journal Article
Details